Morgan Stanley Xenon Pharmaceuticals Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Morgan Stanley holds 387,596 shares of XENE stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

387,596

Previous 129,491 199.32%

Holding current value

$16.8 Million

Previous $4.34 Million 179.26%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$28.23 - $38.37 $7.29 Million - $9.9 Million	258,105 Added 199.32%	387,596 $12.1 Million
Q1 2025 May 15, 2025	BUY	$33.55 - $40.74 $2.06 Million - $2.5 Million	61,429 Added 90.25%	129,491 $4.34 Million
Q4 2024 Feb 14, 2025	SELL	$38.14 - $45.74 $6.56 Million - $7.86 Million	-171,880 Reduced 71.63%	68,062 $2.67 Million
Q3 2024 May 14, 2025	BUY	$36.12 - $43.96 $42,260 - $51,433	1,170 Added 0.49%	239,942 $9.44 Million
Q3 2024 Nov 14, 2024	BUY	$36.12 - $43.96 $42,260 - $51,433	1,170 Added 0.49%	239,942 $9.44 Million
Q2 2024 May 14, 2025	BUY	$36.25 - $43.75 $6.19 Million - $7.47 Million	170,710 Added 250.82%	238,772 $9.31 Million
Q2 2024 Oct 17, 2024	SELL	$36.25 - $43.75 $5.34 Million - $6.45 Million	-147,427 Reduced 38.17%	238,772 $9.31 Million
Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $5.34 Million - $6.45 Million	-147,427 Reduced 38.17%	238,772 $9.31 Million
Q1 2024 Oct 17, 2024	BUY	$42.66 - $50.04 $6.29 Million - $7.38 Million	147,427 Added 61.74%	386,199 $16.6 Million
Q1 2024 Aug 16, 2024	BUY	$42.66 - $50.04 $6.87 Million - $8.06 Million	161,052 Added 71.53%	386,199 $16.6 Million
Q1 2024 May 15, 2024	BUY	$42.66 - $50.04 $6.87 Million - $8.06 Million	161,052 Added 71.53%	386,199 $16.6 Million
Q4 2023 Aug 16, 2024	SELL	$28.7 - $46.46 $391,037 - $633,017	-13,625 Reduced 5.71%	225,147 $10.4 Million
Q4 2023 Feb 13, 2024	SELL	$28.7 - $46.46 $516,542 - $836,187	-17,998 Reduced 7.4%	225,147 $10.4 Million
Q3 2023 Nov 15, 2023	BUY	$34.16 - $39.73 $1.28 Million - $1.49 Million	37,609 Added 18.3%	243,145 $8.31 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $1.3 Million - $1.63 Million	-37,445 Reduced 15.41%	205,536 $7.91 Million
Q1 2023 May 15, 2023	BUY	$33.46 - $40.35 $5.18 Million - $6.25 Million	154,847 Added 175.69%	242,981 $8.7 Million
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $2.32 Million - $2.77 Million	-70,318 Reduced 44.38%	88,134 $3.48 Million
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $25.9 Million - $33.4 Million	-839,620 Reduced 84.12%	158,452 $5.72 Million
Q2 2022 Oct 27, 2022	SELL	$25.44 - $35.16 $11.2 Million - $15.5 Million	-442,099 Reduced 30.7%	998,072 $30.4 Million
Q2 2022 Aug 15, 2022	SELL	$25.44 - $35.16 $11.2 Million - $15.5 Million	-442,099 Reduced 30.7%	998,072 $30.4 Million
Q1 2022 Oct 27, 2022	BUY	$25.09 - $33.13 $11.1 Million - $14.6 Million	442,099 Added 44.3%	1,440,171 $44 Million
Q1 2022 May 13, 2022	BUY	$25.09 - $33.13 $14.3 Million - $18.8 Million	568,087 Added 65.14%	1,440,171 $44 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $13 Million - $29.4 Million	831,348 Added 2040.82%	872,084 $27.2 Million
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $605,336 - $792,315	40,736 New	40,736 $623,000

Others Institutions Holding XENE

# of Institutions

222

Shares Held

72.7M

Call Options Held

336K

Put Options Held

309K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.7B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account